A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )

PHASE3CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

July 15, 2024

Study Completion Date

March 27, 2025

Conditions
Thyroid Eye Disease
Interventions
DRUG

VRDN-001 Phase 3 Cohort (THRIVE)

5 IV Infusions of veligrotug (VRDN-001) 10mg/kg

DRUG

VRDN-001 Placebo

5 IV Infusions of veligrotug (VRDN-001) placebo

Trial Locations (53)

2000

Sydney Eye Hospital, Sydney

2065

North Shore Eye Surgery, Sydney

10003

New York Eye Ear Infirmary of Mount Sinai, New York

14012

Hospital Arruzafa, Córdoba

15706

Complexo Hospiralario Universitario de Santiago-Hospital Medico-Ciruxico de Conxo, Santiago

26506

West Virgina University Eye Insitute, Morgantown

28027

Clinica Universidad de Navarra, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

31008

Clinica Universidad de Navarra, Pamplona

33034

Sina Medical Center, Homestead

33125

Med-Care Research Inc., Miami

33317

Edward Jenner Research Group Center LLC, Plantation

34231

Sarasota Retina Institue, Sarasota

37075

Universitatsmedizin Gottingen, Göttingen

41071

Hospital Universitatio Virgen De La Macarena, Servicio de Oftalmologia, Seville

48026

Fraser Eye Care Center, Fraser

48152

Kahana Oculoplastic & Orbital Surgery, Livonia

49100

CHU d'Angers, Angers

50009

Hospital Universitario Miguel Servet, Servicio de Paseo Isabel La Catdlica1, Zaragoza

55131

Johannes Gutenberg-University Medical Center, Mainz

55455

University of Minnesota, Department of Ophthalmology and Visual Neurosciences, Minneapolis

60462

Vision Medical Research Inc., Orland Park

64108

University Health Diabetes, Endocrinology & Nephrology Center, Kansas City

66103

KU Medical Center, University of Kansas, Kansas City

75012

Centre Hospitalier National D'ophtalmologie, Paris

75013

AP-HP- Hopital de la Pitie Salpetriere, Paris

77030

Baylor College of Medicine (BCM)-Opthalmology, Houston

77074

Neuro-Eye Clinical Trials, Houston

Neuro-Ophthalmology of Texas PLLC, Houston

80045

University of Colorado - Department of Ophthalmology, Aurora

University of Colorado, Aurora

89144

Advanced Research International, LLC, Las Vegas

90033

USC Roski Eye Institute, Los Angeles

90049

MACRO Trials, Inc., Los Angeles

90210

The Private Office of Raymond Douglas, Beverly Hills

92260

Amy Patel Jain, MD, Newport Beach

94158

University of California, San Francisco, San Francisco

94303

Byers Eye Institute/Stanford University, Palo Alto

95207

Senta Clinic, San Diego

02114

Massachusetts Eye and Ear, Boston

02189

Ophthalmic Consultants of Boston, Weymouth

07103

Rutgers-New Jersey Medical School-Newark, Newark

05401

University of Vermont Medical Center, Burlington

06000

CH Nice, Nice

15-879

NZOZ E-Vita, Bialystok

85-870

Specjakistyczny Osrodek Okulistyczny Oculomedica, Bydgoszcz

90-302

Santa Familia PTG Lodz, Lodz

02-507

Panstwowy Instytut Medycsny MSWiA, Warsaw

53-114

4 Wojskowy Szpital Kliniczny z Polikinika SP ZOZ, Wroclaw

08022

Clinica Bonanova de Cirugia Ocular, Barcelona

HA13UJ

Northwick Park Hospital, London

NW1 5QH

Western Eye Hospital Imperial College NHS trust, London

SE1 7EH

Guy's and St. Thomas NHS Trust, London

All Listed Sponsors
lead

Viridian Therapeutics, Inc.

INDUSTRY

NCT05176639 - A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | Biotech Hunter | Biotech Hunter